Citadel Advisors
PRCT icon

Citadel Advisors’s Procept Biorobotics PRCT Stock Holding History

Citadel Advisors’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.34M Buy
53,500
+2,200
+4% +$62K ﹤0.01% 6987
2025
Q4 		$1.61M Buy
51,300
+4,700
+10% +$156K ﹤0.01% 6353
2025
Q3 		$1.66M Buy
46,600
+16,000
+52% +$731K ﹤0.01% 6450
2025
Q2 		$1.76M Sell
30,600
-7,500
-20% -$424K ﹤0.01% 5943
2025
Q1 		$2.22M Sell
38,100
-600
-2% -$41K ﹤0.01% 5334
2024
Q4 		$3.12M Sell
38,700
-300
-0.8% -$25.6K ﹤0.01% 4774
2024
Q3 		$3.12M Buy
39,000
+16,400
+73% +$1.17M ﹤0.01% 4704
2024
Q2 		$1.38M Sell
22,600
-40,900
-64% -$2.43M ﹤0.01% 6000
2024
Q1 		$3.14M Buy
63,500
+10,400
+20% +$495K ﹤0.01% 4700
2023
Q4 		$2.23M Buy
53,100
+19,300
+57% +$657K ﹤0.01% 5171
2023
Q3 		$1.11M Buy
33,800
+33,400
+8,350% +$1.14M ﹤0.01% 6350
2023
Q2 		$14.1K Sell
400
-2,400
-86% -$79.4K ﹤0.01% 13013
2023
Q1 		$79.5K Sell
2,800
-2,800
-50% -$98.8K ﹤0.01% 11563
2022
Q4 		$233K Sell
5,600
-64,800
-92% -$2.78M ﹤0.01% 9829
2022
Q3 		$2.92M Buy
70,400
+52,800
+300% +$2.11M ﹤0.01% 4857
2022
Q2 		$575K Buy
+17,600
New +$640K ﹤0.01% 8320

Other funds holding PRCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CC
Chicago Capital Chicago, Illinois $3.71B AUM 19.51% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors's PRCT Position: Q1 2026 in Review

Citadel Advisors sold out of Procept Biorobotics (PRCT) in Q1 2026, closing a stake of 91,061 shares — an estimated $2.57M sold.

Citadel Advisors first reported a position in PRCT in Q3 2021 and held it in 18 quarters. The position peaked at $36.6M in Q3 2023. 256 funds tracked by Wall St. Rank hold PRCT as of Q1 2026.

  • Citadel Advisors reported no remaining Procept Biorobotics position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 91,061 Procept Biorobotics shares in Q1 2026, an estimated $2.57M.
  • Citadel Advisors first reported a position in Procept Biorobotics in Q3 2021 and held it in 18 quarters.
  • Citadel Advisors's Procept Biorobotics position peaked at $36.6M in Q3 2023.
  • 256 funds tracked by Wall St. Rank held Procept Biorobotics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.